Novel tricalcium silicate/monocalcium phosphate monohydrate composite bone cement

Current bone cements face limitations in setting time and biodegradability. Traditional tricalcium silicate formulations often exhibit long initial setting times, which can hinder clinical application. While these materials show bioactivity, their mechanical properties and pH stability in physiological environments remain areas of concern. Researchers have explored phosphate-based additives to improve cement behavior. However, the precise impact of monocalcium phosphate monohydrate on cement properties has not been fully clarified. This gap motivated investigations into composite systems that balance workability and degradation. No prior work had resolved the optimal phosphate content for both injectability and bioactivity. The need for a cement with shorter setting times and controlled pH remains unmet. This study addresses these limitations through a novel composite approach.

The study aimed to develop a bone cement with improved setting characteristics and bioactivity. The specific problem addressed was the long initial setting time of tricalcium silicate. Researchers sought to incorporate monocalcium phosphate monohydrate to reduce this time. The motivation was to create a cement suitable for minimally invasive procedures. The study also aimed to assess injectability and pH stability in simulated body conditions. Mechanical properties and degradation behavior were evaluated as secondary goals. The researchers focused on optimizing the phosphate content for clinical relevance. They tested multiple weight ratios to identify the most effective formulation. The ultimate goal was to produce a cement with both hydraulic and biological advantages.

The study used a composite system of tricalcium silicate and monocalcium phosphate monohydrate. Four formulations were tested with MCPM at 0%, 10%, 20%, and 30% by weight. Setting times were measured using standard methods. Injectability was assessed with a 2.0 mm nozzle and a liquid-to-powder ratio of 0.8 mL/g. pH changes were monitored in simulated body fluid over time. Compressive strength was tested after 4-28 days of setting. Bioactivity was evaluated by soaking samples in simulated body fluid for seven days. Degradation was analyzed in Tris-HCl solution to assess material breakdown. These methods provided data on mechanical, chemical, and biological performance.

The initial setting time dropped from 90 minutes to 30 minutes at 20% MCPM. The composite paste remained injectable for 2-20 minutes through a 2.0 mm nozzle. pH fluctuations in simulated body fluid were significantly reduced with higher MCPM content. Compressive strength remained slightly lower than pure tricalcium silicate after 4-28 days. Bioactivity tests showed the formation of apatite-like layers after seven days in simulated body fluid. The material degraded in Tris-HCl solution, indicating controlled biodegradability. The 20% MCPM formulation balanced injectability and mechanical performance best. These results suggest the composite offers improved clinical usability and biological integration.

The study found that adding 20% monocalcium phosphate monohydrate improved setting and injectability. The composite cement showed reduced pH variation in simulated body conditions. Compressive strength remained adequate for bone substitute applications. The material demonstrated good bioactivity and controlled degradation in Tris-HCl. These findings suggest the composite could be suitable for bone repair procedures. The authors propose that this cement offers advantages over pure tricalcium silicate. They highlight the balance between hydraulic properties and biological performance. The results support further evaluation of this composite for orthopedic use.